- improving the working of the pharmaceuticals market:
- develop a set of performance and competitiveness indicators (benchmarking);
- shorten the time between granting a marketing authorisation and pricing and reimbursement decisions;
- develop a competitive generic market, tackling intellectual property right issues;
- develop a competitive market for non-prescription medicines;
- find ways of sharing information and data;
- develop a health technology assessment (HTA), including clinical and cost effectiveness;
- improve the use of telematics.
- stimulating innovation and strengthening the European science base:
- improve the legislation and licensing system for introducing innovative medicines on the market;
- create European virtual institutes of health, connecting all competence centres ("network of excellence");
- improve coordination at EU level for clinical trials, a biotechnology strategy, an incentive policy to support research and the marketing of paediatric and orphan medicines;
- no advertising restrictions on non-prescription medicines.
- producing better information for patients:
- legislation on patient information leaflets should be reviewed;
- post-marketing surveillance should be optimised;
- fund European patient groups.
